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Abstract
Objective: To establish whether low HbA1c is associated
with clinical hypoglycaemia among people with type 2 dia-
betes prescribed insulins or sulphonylureas.
Design: Retrospective cohort study using routine elec-
tronic GP health records collected between January 2013
and December 2015.
Setting: Three east London Clinical Commissioning
Groups.
Participants: Two cohorts of adults with type 2 diabetes
prescribed either (i) insulins with or without other oral
antidiabetic medication (n¼ 6788, 36.4%) or (ii) sulphony-
lureas with or without other oral antidiabetic medications
excluding insulins (n¼ 11,840, 63.6%).
Main outcome measures: First clinically recorded hypogly-
caemia and all-cause mortality. Hazard ratios (HR) adjusting
for age, ethnicity, renal function and comorbidities were
calculated using Cox regression models.
Results: Compared with an HbA1c of 53–63mmol/mol,
the adjusted HR of hypoglycaemia in those with a
low HbA1c, below 53mmol/mol, in the insulin and
sulphonylurea cohorts were 1.26 (95% CI, 0.97 to
1.62) and 1.54 (95% CI, 1.27 to 1.87), respectively.
Adjusted HRs of all-cause mortality from low HbA1c in
the insulin and sulphonylurea cohorts were 1.54 (95% CI,
1.15 to 2.07) and 1.42 (95% CI, 1.11 to 1.81), respect-
ively. Increasing age and renal impairment were also asso-
ciated with increased hypoglycaemic risk in both cohorts.
Conclusions: HbA1c below 53mmol/mol was associated
with episodes of clinical hypoglycaemia among people with
type 2 diabetes prescribed sulphonylureas, and all-cause
mortality in those prescribed insulins and sulphonylureas.
These findings support the need for reviewing glycaemic
targets and the intensities of treatment in those with low
HbA1c prescribed insulins or sulphonylureas to reduce the
risk of hypoglycaemia.
Keywords
type 2 diabetes mellitus, hypoglycaemia, glycosylated
haemoglobin A, hypoglycaemic agents, primary health care
Introduction
Type 2 diabetes mellitus therapy focuses on reducing
hyperglycaemia and its sequelae. Increasingly, inten-
sive treatments have been employed to achieve tighter
control of blood glucose. Sulphonylureas and insulin
regimens are recommended as second and third line
agents respectively for people with poorly controlled
type 2 diabetes, and an HbA1c target of 53mmol/mol
is recommended for individuals on these medica-
tions.1 These strategies have been supported by stu-
dies showing an association between reduced
glycaemia and fewer microvascular complications of
diabetes or non-fatal cardiovascular outcomes.2–4
However, meta-analysis of trial data has shown no
signiﬁcant diﬀerence in all-cause or cardiovascular
mortality between those with intensive glycaemic con-
trol versus conventional glycaemic control.
Furthermore, intensive glycaemic control substan-
tially increases the risk of hypoglycaemia.5
Hypoglycaemia is a major clinical consequence of
intensive glucose-lowering therapy and is associated
with falls, fractures and road traﬃc accidents.6–11
However, episodes requiring medical assistance
account for only a minority of cases, with up to
85% medically unreported.12,13 Due to the possible
harms of intensive treatments, recent national and
international guidance has recommended more
relaxed, individualised targets for glycosylated
haemoglobin (HbA1c) in people with type 2 diabetes
at risk of hypoglycaemia such as the frail, elderly or
those with multiple comorbidities.1,14,15 However, the
relationship between hypoglycaemia and HbA1c is
not clear. The early Diabetes Control and
Complications Trial and UK Prospective Diabetes
Study (UKPDS) suggested an inverse relationship
between hypoglycaemic risk and HbA1c.3,16
However, subsequent studies identiﬁed that poor gly-
caemic control, with high HbA1c values, was also
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Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://
www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided
the original work is attributed as specified on the SAGE and Open Access pages (https://uk.sagepub.com/en-us/nam/open-access-at-sage).
Journal of the Royal Society of Medicine Open;
9(7) 1–10
DOI: 10.1177/2054270418773669
associated with hypoglycaemia.12,17–21 Currie et al.
found that post-index mean HbA1c exhibited a
U-shaped association with all-cause mortality: study
subjects with the lowest HbA1c had signiﬁcantly
higher risk for both those on oral therapies including
sulphonylureas and those prescribed insulins.22
Our aim was to establish whether low HbA1c
below 53mmol/mol was prospectively associated
with hypoglycaemia in each of these treatment
groups. Our secondary aim was to identify whether
low HbA1c below 53mmol/mol was prospectively
associated with higher rates of all-cause mortality
among people with type 2 diabetes in east London
prescribed insulins and/or sulphonylureas.
Methods
Setting
The east London boroughs of Tower Hamlets,
Newham and City & Hackney are among the most
ethnically diverse in the UK with high levels of social
deprivation. In April 2013, all 147 general practices in
these localities provided primary care to 953,163
registered people.23
Approximately 50% of the local populations are
from black African/Caribbean (14%) and South
Asian ethnic groups (33%).24 In 2013, the number
of adults registered with diabetes in the three local-
ities was 47,331 with an estimated prevalence of
6.4%.23
As in the rest of the UK, diabetes care is largely
delivered in primary care settings by general practi-
tioners and practice nurses, with all routine care par-
ameters and prescribing recorded in the electronic
health record.
Study design
Using a retrospective cohort study design, we analysed
the electronic health records of patients from 139 out
of 147 general practices in three co-terminous east
London Clinical Commissioning Groups (Tower
Hamlets, Newham and City & Hackney) between 1
January 2013 and 31 December 2015. Data from
eight practices were not available for technical reasons.
We securely extracted non-identiﬁable patient-level
data from the electronic health records of patients
registered with participating practices on 9
September 2016, using pre-speciﬁed search terms.
The criteria for selection of participants included in
the study is detailed in Figure 1.
Those included formed two cohorts: (i) individuals
prescribed insulins with or without other antidiabetic
medication including sulphonylureas; and (ii) those
prescribed sulphonylureas with or without other anti-
diabetic drugs excluding insulins, in the six months
prior to 1 January 2013. Participants were followed
from 1 January 2013 until they experienced an epi-
sode of hypoglycaemia, died, left the GP practice list,
stopped medication for six months or the study
period ended on 31 December 2015. Subjects in the
sulphonylurea cohort who started using insulins
during the study period were censored on the date
insulins were commenced.
The primary outcome of the study was the ﬁrst
record in the primary care electronic health record
of hypoglycaemia during the study period, deﬁned
by one of several speciﬁed Read codes for hypogly-
caemia, hypoglycaemic coma or a documented blood
glucose level below 3.9mmol/L. The secondary out-
come was death from any cause as deﬁned by a coded
registration status of ‘deceased’ in the primary care
electronic health record (see supplementary material
for complete code lists).
The exposure of interest was the last recorded
HbA1c in mmol/mol, in the year prior to 1 January
2013. We deﬁned a low HbA1c as below 53mmol/
mol, optimal HbA1c as 53–63mmol/mol and
increased HbA1c in three categories 64–74, 75–85
and >86mmol/mol.
Data on other potential risk factors for hypogly-
caemia as of 1 January 2013 were collected, including
age, gender, renal function deﬁned by last recorded
estimated glomerular ﬁltration rate (eGFR, ml/min/
1.73m2) in the year prior to 1 January 2013, ethnicity,
body mass index (kg/m2), comorbidities deﬁned using
the Read codes in the Quality and outcomes
Framework ruleset (ischaemic heart disease, stroke,
hypertension, atrial ﬁbrillation, heart failure, chronic
obstructive pulmonary disease, dementia, severe
mental illness, learning disability), duration of type 2
diabetes mellitus and cohort drug use (insulins or
sulphonylureas).25
Statistical analysis
We calculated crude incidence rates of the ﬁrst rec-
orded episode of hypoglycaemia with 95% conﬁdence
intervals per 1000 patient-years across ﬁve HbA1c
categories (<53, 53–63, 64–74, 75–85 and
86mmol/mol) and by each co-variable, in each
cohort. Using Cox proportional hazard modelling,
unadjusted and adjusted hazard ratios for hypogly-
caemia in each HbA1c category were calculated using
53–63mmol/mol (optimal glycaemic control) as the
reference category.
The proportional hazards assumption was tested
using formal tests of interaction between HbA1c cat-
egory and time bands of the follow-up period for each
2 Journal of the Royal Society of Medicine Open 9(7)
cohort using likelihood ratio tests (LRT). The time
bands were generated by splitting the study period
according to tertiles of outcome events across the
entire study period. The proportional hazards
assumption was not violated for either outcome in
both cohorts.
All other co-variables (age, gender, ethnicity,
eGFR, body mass index, comorbidities, duration of
Figure 1. Patients selected for inclusion in the study analysis.
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type 2 diabetes and duration of cohort drug use) were
then included in the adjusted Cox regression models.
We calculated unadjusted and adjusted hazard
ratios of insulin-use versus sulphonylureas without
insulin for each outcome. We then examined the pres-
ence of any interaction between HbA1c, insulins and
sulphonylureas on the risk of hypoglycaemia by test-
ing the suitability of an interaction term in an
adjusted Cox regression model combining the two
cohorts, using likelihood ratio testing.
There were no large discrepancies in missing values
between the two cohorts and thus all co-variables
were included in the full model. Therefore, partici-
pants with missing values were excluded from the
full Cox regression models.
HbA1c categories were tabulated among those lost
to follow-up or censored to look for potential discre-
pancies that might lead to bias in the study’s ﬁndings.
The stated analysis was then repeated for the sec-
ondary outcome, all-cause mortality.
All analyses were undertaken using Stata 14
(StataCorp., Texas, USA).26 Two-sided p values
below 0.05 were considered statistically signiﬁcant.
Results
A total of 18,628 subjects were included in the study
(Figure 1). Of these, 6788 (36.4%) were prescribed
insulins with or without other antidiabetic medication
and 11,840 (63.6%) sulphonylureas with or without
other diabetic medication excluding insulins at base-
line. Among the insulin cohort, 90.1% were pre-
scribed analogue insulins, 9.9% human insulins. Of
those prescribed analogue insulins, 40.1% were on
basal agents. For those in the sulphonylurea cohort,
93.7% were prescribed second-generation sulphony-
lureas, 2.7% ﬁrst-generation and 3.6% third-genera-
tion agents. Of the 11,091 on second-generation
sulphonylureas, 97.0% were prescribed Gliclazide.
During the three-year study period, 2858 (15.3%)
participants left the study population, 1195 (17.6%)
from the insulin cohort and 1663 (14.3%) from the
sulphonylurea cohort. Additionally, 843 (12.4%) of
the insulin cohort and 1862 (16.0%) of the sulphony-
lurea cohort were ineligible for further follow-up
when six months or more had elapsed between their
last prescription and the end of the study period.
Finally, 1256 (10.8%) of the sulphonylurea cohort
were censored because insulin therapy was com-
menced during the study period (Figure 1). The
mean length of follow-up was 2.32 years in the insulin
cohort and 2.22 in the sulphonylurea cohort.
Table 1 shows the baseline characteristics of the
study population and each cohort. The distribution
of baseline HbA1c across those lost to follow-up or
censored can be found in the supplementary
materials.
Hypoglycaemia
Of the participants entering the study, 1315 (7.1%)
had a clinically recorded episode of hypoglycaemia
during the three-year study period, 675 (9.9%) of
the insulin cohort and 640 (5.4%) of those prescribed
sulphonylureas without insulin (Table 2).
After adjusting for all other covariables, the hazard
ratio of ﬁrst recorded hypoglycaemia from lowHbA1c
(<53mmol/mol) in the insulin and sulphonylurea
cohorts were 1.26 (95% CI, 0.97 to 1.63) and 1.54
(95% CI, 1.27 to 1.87), respectively (Figure 2).
We found evidence of interaction between insulin-
use versus sulphonylureas and baseline HbA1c (LRT
p< 0.01). Insulin use was associated with a higher
relative risk of hypoglycaemia versus sulphonylureas
at all levels of HbA1c, with increasing risk in higher
HbA1c categories: hazard ratio 1.27 (95% CI, 1.01 to
1.60) in those with HbA1c< 53mmol/mol; HbA1c
53–63, hazard ratio 1.55 (95% CI, 1.23 to 1.95);
HbA1c 63–74, hazard ratio 2.59 (95% CI, 1.83 to
3.67); HbA1c 75–85, hazard ratio 2.18 (95% CI,
1.38 to 3.45); HbA1c 86, hazard ratio 2.22 (95%
CI, 1.51 to 3.26).
Online supplementary tables show the risk of
hypoglycaemia for the remaining covariables in the
adjusted models for each cohort. In both cohorts,
increasing age, impaired renal function and Black
African/Caribbean ethnicity were associated with
higher risks of clinical hypoglycaemia. Cognitive
impairment was associated with higher hypogly-
caemic risk in the sulphonylurea cohort.
Mortality
There were 1037 deaths among participants during
the study period (5.6%). The adjusted Cox model
demonstrated the highest mortality risks in the
lowest and highest HbA1c categories in both cohorts:
HbA1c< 53mmol/mol, hazard ratio 1.54 (95% CI,
1.15 to 2.07) in those prescribed insulin, hazard
ratio 1.42 (95% CI, 1.11 to 1.81) in the sulphonylurea
cohort; and HbA1c 86mmol/mol, hazard ratio 1.81
(95% CI, 1.37 to 2.39) for insulin users and hazard
ratio 2.06 (95% CI, 1.41 to 3.02) for sulphonylureas
without insulin (Table 2).
After adjusting for all other covariables, insulin-
use was associated with increased mortality risk rela-
tive to sulphonylureas: hazard ratio 1.36 (95% CI,
1.16 to 1.58). There was no evidence of interaction
between cohort medication and baseline HbA1c
(likelihood ratio test p¼ 0.98).
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Discussion
Summary
We found that in the routine use of both insulins and
sulphonylureas, low HbA1c levels below 53mmol/
mol were associated with a signiﬁcant increased risk
of hypoglycaemia. After adjustment for other factors,
this association remained independently associated
with hypoglycaemia in those on sulphonylureas,
while the increased risk among those on insulins
was non-signiﬁcant. At all levels of HbA1c, insulins
were associated with a greater risk of hypoglycaemia
compared to sulphonylureas, particularly among
those with higher HbA1c values. All-cause mortality
Table 1. Baseline characteristics of the insulin and sulphony-
lurea cohorts.
Sulphonylurea Insulin
Variable N (%) N (%)
Total 11840 (100) 6788 (100)
HbA1c (mmol/mol) (%)
<53 (<7.0) 3630 (30.7) 998 (14.7)
53–63 (7.0–7.9) 3644 (30.8) 1679 (24.7)
64–74 (8.0–8.9) 2018 (17) 1502 (22.1)
75–85 (9.0–9.9) 1087 (9.2) 1079 (15.9)
86 (10.0) 1461 (12.3) 1530 (22.5)
Age (n, %)
<55 3032 (25.6) 1456 (21.4)
55–64 3387 (28.6) 1878 (27.7)
65–74 2536 (21.4) 1650 (24.3)
75 2885 (24.4) 1804 (26.6)
Gender
Male 6527 (55.1) 3400 (50.1)
Female 5313 (44.9) 3388 (49.9)
Ethnicity (%)
White 2614 (22.1) 1776 (26.2)
South Asian 6056 (51.1) 3064 (45.1)
Black 2569 (21.7) 1654 (24.4)
Other 526 (4.4) 254 (3.7)
Not recorded 75 (0.6) 40 (0.6)
eGFR (ml/min/1.73 m2)
60 158 (1.3) 320 (4.7)
30–59 1406 (11.9) 1206 (17.8)
<30 8422 (71.1) 3998 (58.9)
Not recorded 1854 (15.7) 1264 (18.6)
BMI
<25 2718 (23) 1158 (17.1)
25–30 4517 (38.2) 2458 (36.2)
30–34 2724 (23) 1819 (26.8)
(continued)
Table 1. Continued.
Sulphonylurea Insulin
Variable N (%) N (%)
Total 11840 (100) 6788 (100)
35 1846 (15.6) 1321 (19.5)
Not recorded 35 (0.3) 32 (0.5)
Duration of diabetes
< 5 years 2739 (23.1) 620 (9.1)
 5 years 8877 (75) 5957 (87.8)
Unknown 224 (1.9) 211 (3.1)
Duration of study drug prescriptions
< 6 months (N, %) 645 (5.4) 311 (4.6)
6–12 months (N, %) 598 (5.1) 325 (4.8)
12 months (N, %) 10597 (89.5) 6152 (90.6)
Comorbidities (%)
Ischaemic heart disease 1607 (13.6) 1673 (24.6)
Stroke 636 (5.4) 595 (8.8)
Hypertension 7409 (62.6) 4696 (69.2)
Atrial fibrillation 322 (2.7) 260 (3.8)
Heart failure 403 (3.4) 570 (8.4)
COPD 2021 (17.1) 1388 (20.4)
Dementia 140 (1.2) 123 (1.8)
SMI 396 (3.3) 245 (3.6)
Learning disability 67 (0.6) 35 (0.5)
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was signiﬁcantly increased in both the low and high-
est HbA1c categories, particularly among those pre-
scribed insulins.
Strengths and limitations
Many prior studies examining the relationship of
HbA1c and hypoglycaemia included only severe
cases of hypoglycaemia that required third party
assistance and/or hospital admission, usually with a
blood glucose of less than 3.0mmol/L or those who
recovered after administration of glucose or gluca-
gon.3,17,19,20 We identiﬁed hypoglycaemia codes rec-
orded in primary care electronic clinical records and/
or primary care recorded blood glucose measure-
ments below 3.9mmol/L to capture all severities of
hypoglycaemia. Furthermore, we did not exclude
patients with previous hypoglycaemia. Therefore,
our ﬁndings are likely to be generalisable to estab-
lished populations with type 2 diabetes treated with
either insulins or sulphonylureas.
It is likely that most hypoglycaemia was self-man-
aged without healthcare involvement and thus not
recorded at all.12 By using coded data and laboratory
measurements rather than free-text information from
the patient records, we were unable to determine the
clinical severity of the recorded hypoglycaemic
events, whether asymptomatic, mild or requiring the
assistance of others. We were also unable to access
participants’ hospital records and thus may have
missed hospital episodes that were not recorded in
the GP records. Given that only 4.7% of all instances
of hypoglycaemia are reported to a medical profes-
sional, episodes leading to hospital attendance are
likely to represent only a small proportion of
cases.12 This potential omission of more serious
cases is likely to have led to an underestimation of
the strength of association we observed between
HbA1c and hypoglycaemia, but is unlikely to have
inﬂuenced its direction.
During the study period, 15.3% of participants
were censored because they left their respective prac-
tices. However, there were no major discrepancies in
the distribution of baseline HbA1c among those who
left their practices compared to those that remained.
Larger proportions of subjects who stopped their
medication for six months or more had lower baseline
HbA1c than their respective cohorts at the start of the
study. Reasons for stopping medication may have
included side eﬀects such as unreported hypogly-
caemia, possibly underestimating the association of
low HbA1c and hypoglycaemia.
This study is subject to the limitations of any rou-
tinely collected data where coding of information
may have varied in quality and extent between clin-
icians. However, we think this is unlikely to have
caused systematic biases that would have substan-
tially inﬂuenced our results. Medication doses were
Figure 2. Hazard ratios of first recorded hypoglycaemic events by HbA1c category stratified by hypoglycaemic agent (adjusted
Cox regression models).
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not available for this study, preventing analysis of the
eﬀect of insulin or sulphonylurea dosage.
Additionally, we did not include participants’ other
concurrent medications in our analysis and were
unable to account for any eﬀect these might have
had on our ﬁndings.
A limitation of this study is the use of a single
baseline HbA1c measurement from which the risk
estimates for both the primary and secondary out-
comes were derived. Other similar studies have used
a variety of methods to calculate mean HbA1c from
multiple measurements to account for an individual’s
overall glycaemic control during the respective study
periods.22,27,28 We opted to use a single baseline
exposure measurement to identify disparities in risk
as a pragmatic decision because such an approach can
be easily deployed in electronic health record-based
risk prediction tools in primary care.
This study measured time to the ﬁrst hypoglycaemic
event and does not account for disparities in the fre-
quency of hypoglycaemia by HbA1c experienced by
subjects. Collecting data on multiple hypoglycaemic
events during the study period and conducting a
random eﬀects Poisson regression analysis may pro-
vide more robust estimates of the associations between
hypoglycaemia and HbA1c but there are challenges
inherent to such an approach, most notably distin-
guishing discrete episodes from multiple recordings
of the same event, particularly when using both clinical
codes and laboratory measurements.
Comparison with existing literature
Our ﬁndings support those of previous studies that
found increased risks of hypoglycaemia with low
HbA1c. Chan et al., who pooled data from three
randomised controlled trials comparing insulin prep-
arations combined with metformin, demonstrated a
statistically signiﬁcant relationship of low HbA1c
and hypoglycaemia.29 Subjects in the UK
Prospective Diabetes Study trial treated with insulins
or sulphonylureas who achieved lower median
HbA1c experienced more hypoglycaemia.16 In con-
trast, the ACCORD study found higher HbA1c at
baseline was associated with an increased risk of
hypoglycaemia in both the intensive and standard
treatment arms.20 However, the ACCORD study
aimed to reduce HbA1c rapidly predominantly
using insulin. Those in whom HbA1c did not fall
quickly were at higher risk of hypoglycaemia, which
the authors postulate may have been due to unsuc-
cessful further intensiﬁcations of therapy.
The Diabetes and Aging Study suggested a
U-shaped trend of raised hypoglycaemic risk with
both low and high glycosylated haemoglobin, but
we found no signiﬁcant evidence of such a relation-
ship (Figure 2).21
In line with previous research, we found higher inci-
dence rates of hypoglycaemia in the insulin cohort
compared to those on sulphonylureas.7,16 However,
we found a signiﬁcant interaction of risk between insu-
lin-use relative to sulphonylureas and baseline HbA1c,
in which the relative risk of hypoglycaemia associated
with insulin use was greater at higher HbA1c levels.
Such individuals with poorly controlled diabetes are
likely to be treated with higher insulin doses and
thus at greater hypoglycaemic risk.12 This may also
account for the ﬁndings of the ACCORD study in
which most patients were prescribed insulins.20
Like Currie et al. who examined a national
General Practice database, our analysis demonstrated
higher mortality in both those with low and highest
HbA1c in both the insulin and sulphonylureas
cohorts.22 The mortality risk from low HbA1c was
slightly higher among those prescribed insulins but
was also signiﬁcantly raised in those in the sulphony-
lurea cohort, in contrast to the ﬁndings of Monami
et al.27 Theirs was a smaller nested case-control study,
which found HbA1c below 6.5% (48mmol/mol) to be
associated with signiﬁcantly higher mortality risk in
those treated with insulins, adjusting for metformin
exposure and renal insuﬃciency only.
Implications for clinical practice and research
Identifying patients with a HbA1c below 53mmol/
mol prescribed insulins or sulphonylureas, particu-
larly the elderly, those with renal and cognitive
impairment for medicines review may provide an
opportunity to optimise glycaemic control to more
relaxed targets that reduce both hypoglycaemic and
mortality risk.
This study explored disparities in time to ﬁrst rec-
orded hypoglycaemic event by a single baseline
HbA1c. Further research using linked primary and sec-
ondary care health records is needed to examine the
eﬀect of HbA1c on the risk of multiple hypoglycaemic
events using analysis methods that accurately account
for the time-varying nature of HbA1c.
Conclusion
Individuals with type 2 diabetes on sulphonylureas or
insulin with low HbA1c< 53mmol/mol were at
increased risk of experiencing episodes of clinical
hypoglycaemia in comparison to those with more
optimal levels of HbA1c, though only signiﬁcantly
so in the sulphonylurea cohort. Mortality exhibited
a U-shaped curve, with the greatest risk associated
with low and highest HbA1c categories in users of
8 Journal of the Royal Society of Medicine Open 9(7)
both insulins and sulphonylureas. Insulin users were
at higher overall risk of both hypoglycaemia and
mortality than those on sulphonylureas. In people
with low HbA1c at increased hypoglycaemic risk,
more relaxed glycaemic targets and de-intensiﬁcation
of insulins and/or sulphonylureas may reduce hypo-
glycaemia and mortality.
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